Class III β-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4511-4516

  Galmarini, Carlos M ^a   Treilleux, Isabelle ^b   Cardoso, Fatima ^c   Bernard Marty, Chantal ^c   Durbecq, Virginie ^c   Gancberg, David ^d   Bissery, Marie Christine ^e   Paesmans, Marianne ^c   Larsimont, Denis ^c   Piccart, Martine J ^c   Di Leo, Angelo ^f   Dumontet, Charles ^a,g  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE LÉON BÉRARD   (France)

^c JULES BORDET INSTITUTE   (Belgium)

^d JOINT RESEARCH CENTRE   (Italy)

^e SANOFI   (France)

^f HOSPITAL OF PRATO   (Italy)

^g INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAU PROTEIN; ANTINEOPLASTIC AGENT; ISOPROTEIN; TAXOID; TUBULIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; BREAST TUMOR; DRUG RESISTANCE; FEMALE; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROTEIN ISOFORMS; TAXOIDS; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 51649107171     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4741     Document Type: Article

References (45)

1. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001;6:133-46.
2. Mouridsen HT. Systemic therapy of advanced breast cancer. Drugs 1992:44 Suppl 4:17-28.
3. Henderson IC, Frei E III. Adriamycin cardiotoxicity. Am Heart J 1980;99:671-4.
4. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JAA. Clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973;32:302-14.
5. Unverferth DV, Magorien RD, Leier CV, Balcerzak SP. Doxorubicin cardiotoxicity. Cancer Treat Rev 1982:9: 149-64.
6. Kennedy MJ, Donehower RC, Rowinsky EK. Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide. Semin Oncol 1995;22: 23-7.
7. Fumoleau P, Seidman AD. Trudeau ME, Chevallier B, Ten Bokkel Huinink WW. Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opin Investig Drugs 1997;6:1853-65.
8. van Oosterom AT. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. Semin Oncol 1995;22:22-8.
9. Konecny GE. Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004;96:1141-51.
10. Di Leo A, Chan S, Paesmans DH, et al. ER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with singleagent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004;86:197-206.
11. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000;11:647-63.
12. Van Poznak C. Tan L, Panageas KS, et al. Assessment of molecular markers of clinical sensitivity to singleagent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-26.
13. 1 arrest. Cancer Res 1998;58:396-401.
14. Sjostrom J, Blomqvist C, Heikkila P, et al. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2000;6:3103-10.
15. Lissoni P, Fugamalli E, Malugani F, et al. Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during Taxol therapy in metastatic breast cancer. Int J Biol Markers 2000;15: 308-11.
16. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (Taxol) and docetaxel (Taxotere). Int J Cancer 2003;104:121-9.
17. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93.
18. Verdier-Pinard P. Wang F, Martello L, Burd B, Orr GA, Horwitz SB. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 2003;42:5349-57.
19. Galmarini CM, Kamath K, Vanier-Viornery A. et al. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer 2003;88:1793-9.
20. Rouzier R. Rajan R, Wagner P, et al. Microtubuleassociated protein τ: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005;102: 8315-20. Epub 2005 May 24.
21. Dozier JH, Hiser L, Davis J, et al. β class II tubulin predominates in normal and tumor breast tissues. Breast Cancer Res 2003;5:R157-69.
22. Bernard-Marty C, Treilleux I, Dumontet C, et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer 2002;3:341-5.
23. Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005; 16 Suppl 4:iv14-19.
24. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-54.
25. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-14.
26. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti-Canc Agents 2002;2:1-17.
27. Sullivan KF. Structure and utilization of tubulin isotypes. Annu Rev Cell Biol 1988;4:687-716.
28. Fromes Y, Gounon P, Veitia R, Bissery MC, Fellous A. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J Protein Chem 1996;15;377-88.
29. Itoh TJ, Hotani H. Microtubule-stabilizing activity of microtubule-associated proteins (MAPs) is due to increase in frequency of rescue in dynamic instability: shortening length decreases with binding of MAPs onto microtubules. Cell Struct Funct 1994;19: 279-90.
30. Lu Q, Luduena RF. In vitro analysis of microtubule assembly of isotypically pure tubulin dimers: intrinsic differences in the assembly properties of αβll, αβIII, and αβIV tubulin dimers in the absence of microtubule-associated proteins. J Biol Chem 1994;269: 2041-7.
31. Panda D, Jordan MA, Chu KC, Wilson L. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J Biol Chem 1996;271: 29807-12.
32. Banerjee A, Roach MC, Trcka P, Luduena RF. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of β-tubulin J Biol Chem 1990:265:1794-9.
33. Dumontet C, Isaac S, Souquet PJ. et al. Expression of class III β tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy - Bull Cancer 2005;92:E25-30.
34. Mozzetti S, Ferlini C, Concolino P, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005;11:298-305.
35. Seve P, Isaac S. Tredan O, et al. Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbinebased chemotherapy. Clin Cancer Res 2005;11: 5481-6.
36. Seve P, Mackey J, Isaac S, et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005;4:2001-7.
37. Seve P, Reiman T, Lai R, et al. Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 2007;60:27-34.
38. Katsetos CD, Draberova E, Smejkalova B, et al Class III β-tubulin and gamma-tubulin are coexpressed and form complexes in human glioblastoma cells. Neurochem Res 2007;32:1387-98. Epub 2007 Apr 4.
39. Lee KM, Cao D, Itami A, et al Class III β-tubulin. a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 200751:539 46 Epub 2007 Aug 21.
40. Gan PP Pasquier E, Kavallaris M. Class III β-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer Cancer Res 2007:67 9356-63.
41. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified β-tubulin isotypes Biochemistry 1997:36 3554-62.
42. Lu Q, Luduena RF. Removal of β III isotype enhances Taxol induced microtubule assembly. Cell Struct Funct 1993;18:173-82.
43. Jaffrezou JP, Dumontet C, Derry WB, et al. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res 1995;7:517-27
44. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB. Altered expression of Mβ2, the class II β-tubulin isotype. in a murine J774 2 celt line with a high level of Taxol resistance J Biol Chem 1995;270:31269-75.
45. Kavallaris M. Tait AS. Walsh BJ, et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001: 61:5803-9